Skip to main content
SpringerLink
Log in

Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient

  • Letter to the Editor
  • Published:
Neurological Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data Availability

Data and material are available upon request of qualified researchers.

References

  1. Tesfa D, Palmblad J (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 4(6):619–625. https://doi.org/10.1586/ehm.11.62

    Article  CAS  PubMed  Google Scholar 

  2. Rigal J, Ciron J, Lépine Z, Biotti D (2020) Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases. Mult Scler Relat Disord 41:102019. https://doi.org/10.1016/j.msard.2020.102019

    Article  CAS  PubMed  Google Scholar 

  3. Auer M, Bsteh G, Hegen H et al (2020) Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab. Mult Scler Relat Disord 43:102155. https://doi.org/10.1016/j.msard.2020.102155

    Article  PubMed  Google Scholar 

  4. Zanetta C, Robotti M, Nozzolillo A et al (2020) Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature. J Neurol Sci 409:116603. https://doi.org/10.1016/j.jns.2019.116603

    Article  PubMed  Google Scholar 

  5. Cohen BA (2019) Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology 92(9):435–436. https://doi.org/10.1212/WNL.0000000000006924

    Article  PubMed  Google Scholar 

  6. Baird-Gunning J, Yun J, Stevenson W, Ng K (2021) Severe delayed-onset neutropenia induced by ocrelizumab. Neurohospitalist 11(1):59–61. https://doi.org/10.1177/1941874420936438

    Article  PubMed  Google Scholar 

  7. Chaiwatanatorn K, Lee N, Grigg A et al (2003) Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 121(6):913–918. https://doi.org/10.1046/j.1365-2141.2003.04385.x

    Article  PubMed  Google Scholar 

  8. Coakley G, Iqbal M, Brooks D et al (2000) CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty’s and large granular lymphocyte syndromes. Arthritis Rheum 43(4):834–843. https://doi.org/10.1002/1529-0131(200004)43:4%3c834::AID-ANR14%3e3.0.CO;2-H

    Article  CAS  PubMed  Google Scholar 

  9. Egawa T, Kawabata K, Kawamoto H et al (2001) The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 15(2):323–334. https://doi.org/10.1016/s1074-7613(01)00185-6

    Article  CAS  PubMed  Google Scholar 

  10. Dunleavy K, Hakim F, Kim HK et al (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106(3):795–802. https://doi.org/10.1182/blood-2004-08-3198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Weng WK, Negrin RS, Lavori P, Horning SJ (2010) Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol 28(2):279–284. https://doi.org/10.1200/JCO.2009.25.0274

    Article  CAS  PubMed  Google Scholar 

  12. Monaco WE, Jones JD, Rigby WF (2016) Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature. Clin Rheumatol 35(10):2457–2462. https://doi.org/10.1007/s10067-016-3313-y

    Article  PubMed  Google Scholar 

  13. Openshaw H, Stuve O, Antel JP et al (2000) Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 54(11):2147–50. https://doi.org/10.1212/wnl.54.11.2147

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departamento de Neurología, Fleni, Montañeses 2325, 1428, Buenos Aires, Argentina

    Mariano Marrodan, José Férnandez & Jorge Correale

  2. Servicio de Hematología, Departamento de Medicina Interna, CEMIC, Buenos Aires, Argentina

    Julia Laviano, Florencia Fornillo & José Férnandez

  3. Departamento de Medicina Interna, Fleni, Buenos Aires, Argentina

    Sofía Oneto, Fabricio M. Reino & Ricardo Delorme

Authors
  1. Mariano Marrodan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Laviano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sofía Oneto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fabricio M. Reino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ricardo Delorme
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florencia Fornillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. José Férnandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jorge Correale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mariano Marrodan.

Ethics declarations

Ethics approval

Fleni’s Institutional Review Board approved the publication of this manuscript.

Consent to participate

The patient consented to the publication of this article anonymously.

Conflict of interest

The authors declare no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marrodan, M., Laviano, J., Oneto, S. et al. Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient. Neurol Sci 42, 3893–3895 (2021). https://doi.org/10.1007/s10072-021-05357-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-021-05357-1

Search

Navigation